Table 2 Baseline characteristics, clinical features and main investigations of the study population
From: Stroke risk after transient ischemic attack in a Norwegian prospective cohort
Variable | n (%) |
|---|---|
Age in years, mean ± SD | 70.5 ± 11.0 |
Age > 60 years | 489 (84.7) |
Male | 327 (56.7) |
Evaluation within 24 h. of TIA onset | 493 (85.4) |
Medical history | |
Former TIA | 101 (17.5) |
Former ischemic stroke | 87 (15.1) |
Former myocardial infarction | 67 (11.6) |
Diabetes mellitus | 66 (11.4) |
Hypertension | 311 (53.9)a |
Hypercholesterolemia | 216 (37.4)b |
Current smoker | 94 (16.3) |
Former smoker | 222 (38.5) |
Modified Rankin score | |
0 | 282 (48.9) |
1 | 195 (33.8) |
2 | 79 (13.7) |
3 | 21 (3.6) |
Clinical features | |
Speech disturbances | 277 (48) |
Hemiparesis of arm | 193 (33.4) |
Hemisensory loss | 134 (23.2) |
Hemiparesis of leg | 115 (19.9) |
Hemiparesis of face | 115 (19.9) |
Hemianopsia | 36 (6.2) |
Amaurosis fugax | 21 (3.6) |
Diplopia | 19 (3.3) |
Investigations | |
Brain CT | 564 (97.7) |
Acute infarction | 13/564 (2.3) |
Brain DWI-MRI | 361 (62.6) |
Acute infarction | 97/361 (26.9) |
Extracranial imaging | 520 (90.1) |
Significant stenosis or occlusion | 48/520 (9.2) |
ECG and/or 24-h Holter ECG | 577 (100) |
Newly diagnosed and known | |
atrial fibrillation and flutter | 79/577 (13.7) |
Medication | At baseline At discharge |
Aspirin | 162 (28.1) 179 (31.0) |
Other antiplatelet agent | 12 (2.1) 36 (6.2) |
Aspirin + other antiplatelet agent | 59 (10.2) 284 (49.2) |
Anticoagulation | 56 (9.7) 91 (15.8) |
Blood-pressure lowering agent | 311 (53.9) 356 (61.7) |
Lipid-lowering agent | 216 (37.4) 483 (83.7) |